https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36595 Wed 27 Apr 2022 14:47:09 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14800 = 20 news reports (total 2350 stories); nine of these cost more than AU$10,000 per course or year of treatment. For these 18 medicines, 31% of stories appeared in the six months prior to the PBAC meeting, 14% in the meeting month and 33% in the six months post-meeting. 38% of the stories had >= 3 medicine mentions, 37% referred to the PBS, 24% to cost to the patient, and 9% cost to Government. There was active patient lobby group campaigning in support of listing of infliximab and pemetrexed; the stories for ADHD were often more negative, referring to the dangers of the medicines and sometimes questioning the appropriateness of treatment and public subsidy. There was little discussion of the PBAC's evidence-based decision-making processes. Conclusions: While there was no general trend to increased news reporting associated with PBAC meetings, some drugs did attract media attention. With more new and expensive drugs, decisions on public funding will become increasingly difficult. The media have an important role in enhancing public understanding of the issues around resource allocation. Specialist journalists, guidelines and checklists may help reporting.]]> Wed 11 Apr 2018 11:22:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44248 U-test) were used to explore associations between responses and previous experience with medicines. Key findings: The most important factors when purchasing NPMs were effectiveness and safety. However, personal experience was the most common method of determining effectiveness. Most respondents believed buying NPMs in pharmacies gave access to advice, but were less likely to agree that pharmacies were associated with safe and effective treatments. Around half the respondents agreed that it is wrong to sell treatments lacking scientific evidence; many also agreed that it is up to consumers to decide what they want even without scientific evidence. Individuals experiencing an ineffective NPM were less likely to trust scientific evidence of efficacy as the sole source of effectiveness information; regular prescription medicine users often agreed that scientific evidence is needed to support effectiveness. Conclusions: Consumers have conflicting views regarding the need for scientific evidence and the desire for patient autonomy in NPM purchases. This presents a challenge for pharmacists wishing to maintain professional obligations to provide evidence-based treatments to consumers.]]> Tue 11 Oct 2022 12:14:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28262 Thu 13 Jan 2022 10:30:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36636 Thu 09 Dec 2021 11:03:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1146 Sat 24 Mar 2018 08:32:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1788 Sat 24 Mar 2018 08:27:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14683 Sat 24 Mar 2018 08:19:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10532 Sat 24 Mar 2018 08:13:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18164 90% of general practices computerized. Recent eHealth incentives promote the use of up to date electronic information sources relevant to general practice with flexibility in mode of access. Objective: To determine GPs’ access to and use of electronic information sources and computerized clinical decision support systems (CDSSs) for prescribing. Methods: Semi-structured interviews were conducted with 18 experienced GPs and nine GP trainees in New South Wales, Australia in 2008. A thematic analysis of interview transcripts was undertaken. Results: Information needs varied with clinical experience, and people resources (specialists, GP peers and supervisors for trainees) were often preferred over written formats. Experienced GPs used a small number of electronic resources and accessed them infrequently. Familiarity from training and early clinical practice and easy access were dominant influences on resource use. Practice time constraints meant relevant information needed to be readily accessible during consultations, requiring integration or direct access from prescribing software. Quality of electronic resource content was assumed and cost a barrier for some GPs. Conclusions: The current Australian practice incentives do not prescribe which information resources GPs should use. Without integration into practice computing systems, uptake and routine use seem unlikely. CDSS developments must recognize the time pressures of practice, preference for integration and cost concerns. Minimum standards are required to ensure that high-quality information resources are integrated and regularly updated. Without standards, the anticipated benefits of computerization on patient safety and health outcomes will be uncertain.]]> Sat 24 Mar 2018 08:04:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:213 Sat 24 Mar 2018 07:43:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:389 Sat 24 Mar 2018 07:42:31 AEDT ]]>